Adaptiiv Signs Leading Canadian Cancer Centre as a Collaboration Partner
HALIFAX, Feb. 21, 2019 /CNW/ - Adaptiiv Medical Technologies Inc. (Adaptiiv) is pleased to announce that the Centre Hospitalier de l'Université de Montréal (CHUM) has become its latest Collaboration Partner. The two organizations have agreed to work together to design, develop, and validate a new solution for surface and intracavitary brachytherapy within Adaptiiv's 3DBolus Software.
The Centre Hospitalier de l'Universite de Montreal is an innovative hospital devoted to serving patients. It provides the highest quality specialized and ultraspecialized care to patients and the general public all over Quebec. Through its unique expertise and innovations, its aim is to improve the health of the adult and aging population. As the Université de Montréal hospital, CHUM is dedicated to care, research, teaching, health promotion, and the assessment of technology and health intervention methods in order to continually improve the quality of care and the health of the population. Since the fall of 2017, patients and their families have been able to enjoy a renewed hospital experience at CHUM's new facilities.
"We are excited to be a part of this groundbreaking technology," says François DeBlois, Physics Department Head, Radiation Oncology at CHUM. DeBlois is thrilled about the collaboration opportunity. "Adaptiiv is the first company to offer a platform that fully integrates into the existing treatment workflow and their team has demonstrated the ability to rapidly develop and validate new ideas that can be used in treatment today. The opportunity to work in consultation with Adaptiiv to develop and showcase new brachytherapy applications can lead to tremendous breakthroughs in radiation therapy," says DeBlois.
Adaptiiv's 3DBolus Software provides practitioners with a turnkey software solution that enables 3D printing of patient-specific devices for use in radiation therapy. Devices created using Adaptiiv's software conform to the patient anatomy to improve dose delivery and the patient experience. Patients are more comfortable throughout the treatment period and because the software fully integrates with a cancer centre's treatment planning system, set-up and production times are drastically reduced.
"We are very pleased to make this announcement," says Adaptiiv CEO, Peter Hickey. "By working with François and his team at CHUM, Adaptiiv continues to make significant strides in the battle against cancer by introducing our breakthrough technology into real world applications."
Adaptiiv is the first company in the world to receive US FDA 510(k) clearance to market its 3D printing software for use in radiation oncology. The company's software is used in the United States, Canada, Australia, Israel, Ireland, Hong Kong, and England.
Adaptiiv Medical Technologies Inc. is the definitive software platform to design 3D printed medical devices for use in radiation oncology. Headquartered in Halifax, Nova Scotia, Canada, Adaptiiv is shaping the future of patient-specific healthcare through innovation and collaboration with leading cancer centers throughout the world. Adaptiiv has US FDA 510(k) clearance, is ISO 13485 certified, and has received a CE Mark.
SOURCE Adaptiiv Medical Technologies Inc.